Elder Granger - 10 Nov 2021 Form 4 Insider Report for Better Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Nov 2021, 16:17:35 UTC
Prior SEC filing: 05 Oct 2021
Next SEC filing: 02 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Mark Heinen, Attorney-in-Fact

Key filing fact

Elder Granger filed Form 4 for Better Therapeutics, Inc. on 15 Nov 2021.

Key facts

This page summarizes Elder Granger's Form 4 filing for Better Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Nov 2021, 16:17.

Change

Previous filing in this sequence was filed on 05 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +28,300
Change %
Price: $0.000000
Shares after: 28,300
Date: 10 Nov 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,300
Exercise price: $10.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 1/3 of the shares subject to the stock option on November 10, 2022 and the remaining shares vest in 24 equal monthly installments thereafter; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Issuer or otherwise ceases to serve as a director of the Issuer prior to any such vesting date. The stock option shall accelerate pursuant to the terms of the Non-Employee Director Compensation Policy of the Issuer. The stock option was granted on November 10, 2021.